Business Wire | Jul 29, 2020 04:30PM EDT

ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference

Jul. 29, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 29, 2020--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40th Annual Canaccord Genuity Virtual Growth Conference. The presentation is scheduled for August 12, 2020 at 9:00am ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website on www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005652/en/

CONTACT: INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O'Konek 781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting Robert Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com